SMP200800012B - Composizioni per ridurre l'incidenza di aritmia indotta da farmaco - Google Patents

Composizioni per ridurre l'incidenza di aritmia indotta da farmaco

Info

Publication number
SMP200800012B
SMP200800012B SM200800012T SM200800012T SMP200800012B SM P200800012 B SMP200800012 B SM P200800012B SM 200800012 T SM200800012 T SM 200800012T SM 200800012 T SM200800012 T SM 200800012T SM P200800012 B SMP200800012 B SM P200800012B
Authority
SM
San Marino
Prior art keywords
incidence
drug
compositions
reduce
induced arrhythmia
Prior art date
Application number
SM200800012T
Other languages
English (en)
Other versions
SMAP200800012A (it
Inventor
Joseph Michael Ii Sprafka
Jose Mauro Goulart-Brum
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SMP200800012B publication Critical patent/SMP200800012B/it
Publication of SMAP200800012A publication Critical patent/SMAP200800012A/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM200800012T 2005-07-22 2006-07-20 Composizioni per ridurre l'incidenza di aritmia indotta da farmaco SMAP200800012A (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70155505P 2005-07-22 2005-07-22
PCT/IB2006/052496 WO2007010498A2 (en) 2005-07-22 2006-07-20 Compositions for reducing the incidence of drug induced arrhythmia

Publications (2)

Publication Number Publication Date
SMP200800012B true SMP200800012B (it) 2008-02-27
SMAP200800012A SMAP200800012A (it) 2008-02-27

Family

ID=37547445

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200800012T SMAP200800012A (it) 2005-07-22 2006-07-20 Composizioni per ridurre l'incidenza di aritmia indotta da farmaco

Country Status (19)

Country Link
US (2) US8183284B2 (it)
EP (1) EP1906966A2 (it)
JP (1) JP4880685B2 (it)
KR (1) KR20080017489A (it)
CN (1) CN101227908A (it)
AR (1) AR055091A1 (it)
AU (1) AU2006271230A1 (it)
BR (1) BRPI0613670A2 (it)
CA (1) CA2615975C (it)
IL (1) IL188831A0 (it)
MA (1) MA29622B1 (it)
MX (1) MX2008001063A (it)
NO (1) NO20080890L (it)
PE (1) PE20070369A1 (it)
RU (1) RU2376994C2 (it)
SM (1) SMAP200800012A (it)
TW (1) TW200744613A (it)
WO (1) WO2007010498A2 (it)
ZA (1) ZA200800564B (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105534976A (zh) * 2016-01-14 2016-05-04 山东大学 2-(2,2-二苯基环丙基)-4,5-二氢-1h-咪唑在制备抗神经退化性疾病药物中的应用
JP7042256B2 (ja) 2016-05-19 2022-03-25 タブラ・ラサ・ヘルスケア，インコーポレーテッド 薬剤関連毒性が低減した治療法および処方薬に起因する患者危害の可能性を確認する方法
EP3569249A4 (en) * 2016-12-27 2020-11-11 Osaka University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE
KR20210072013A (ko) * 2018-11-02 2021-06-16 (주)셀트리온 비후성 심근증 치료용 약학 조성물
BR112022001422A2 (pt) * 2019-07-29 2022-03-22 Matthias Rath Ascorbato na prevenção da calcificação vascular induzida por estatina
CN121606573A (zh) * 2026-02-03 2026-03-06 上海市东方医院（同济大学附属东方医院） 一种用于预防或者治疗心肌梗死后室性心律失常的药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742544A (en) 1952-02-23 1955-12-30 Kodak Ltd Enteric products
FR2833M (it) 1962-06-12 1964-10-05 I N I C O Ind Nuclear Invest C
GB1142757A (en) 1967-01-26 1969-02-12 Carter Wallace Therapeutic compositions
ZA701983B (en) 1969-03-24 1971-01-27 Monsanto Co Improved effervescent compositions
US3887700A (en) 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
JPS58126879A (ja) 1982-01-25 1983-07-28 Nippon Chemiphar Co Ltd 光学活性なピペラジン誘導体ならびに心筋梗塞の予防および治療剤
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
WO1990009185A1 (en) 1989-02-16 1990-08-23 Angio-Medical Corp. Composition and method for treatment of gastric and duodenal ulcers and mucosal erosions
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
JP3228347B2 (ja) 1991-06-25 2001-11-12 三菱化学株式会社 シクロプロペノン誘導体
DK0603769T3 (da) 1992-12-25 1999-06-14 Mitsubishi Chem Corp Alfa-aminoketonderivater
US6316487B1 (en) * 1993-06-16 2001-11-13 Aryx Therapeutics Compounds for treatment of cardiac arrhythmia synthesis, and methods of use
AU5787996A (en) 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE493983T1 (de) 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
WO2000040232A2 (en) 1999-01-08 2000-07-13 Bacaner Marvin B Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
FR2838057B1 (fr) 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
EP1501546B1 (de) 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
US20050101565A1 (en) 2002-07-03 2005-05-12 Esperion Therapeutics, Inc. Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders
US20050142129A1 (en) 2002-10-15 2005-06-30 Mangano Dennis T. Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Also Published As

Publication number Publication date
CA2615975C (en) 2012-11-27
US8183284B2 (en) 2012-05-22
CA2615975A1 (en) 2007-01-25
ZA200800564B (en) 2008-12-31
CN101227908A (zh) 2008-07-23
JP2009502773A (ja) 2009-01-29
WO2007010498A3 (en) 2007-05-31
IL188831A0 (en) 2008-08-07
JP4880685B2 (ja) 2012-02-22
MA29622B1 (fr) 2008-07-01
RU2007148908A (ru) 2009-08-27
EP1906966A2 (en) 2008-04-09
TW200744613A (en) 2007-12-16
NO20080890L (no) 2008-03-03
WO2007010498A2 (en) 2007-01-25
AU2006271230A1 (en) 2007-01-25
SMAP200800012A (it) 2008-02-27
KR20080017489A (ko) 2008-02-26
US20120178724A1 (en) 2012-07-12
RU2376994C2 (ru) 2009-12-27
PE20070369A1 (es) 2007-05-16
MX2008001063A (es) 2008-03-19
AR055091A1 (es) 2007-08-08
BRPI0613670A2 (pt) 2011-01-25
US20070021395A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
IL218524A0 (en) Compositions and methods relating to novel compounds and targets thereof
ZA200802723B (en) Modified 4'-nucleosides as antiviral agents
EP2007373A4 (en) INHIBITION OF ALPHA SYNUCLEINE TOXICITY
EP2138540A4 (en) IMPACT DAMPING COMPOSITION
EP1924430A4 (en) ADVANCED FIREPLATES FOR REACHING FROST EFFECTS
BRPI0819070A2 (pt) "composição energética comestível"
GB0501835D0 (en) Improvements relating to spray dried compositions
GB0307671D0 (en) Improvements relating to the construction of playing surfaces
EP1967534A4 (en) ADHESIVE COMPOSITION
IL190466A0 (en) Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia
EP1789800A4 (en) Ileitis DIAGNOSTIC TEST
GB0406870D0 (en) Improvements relating to the production of lantibiotics
IL189547A0 (en) Synthesis of 1??-fluoro-25-hydroxy
EP1872125A4 (en) ISOLATION OF INHIBITOR OF IRES-MEDIATED TRANSLATION
FR2881669B1 (fr) Brasure en alliage d'aluminium
EP1943337A4 (en) COMPOSITION FOR THROMBOZYTE AGGREGATION INHIBITORS
EP1873240A4 (en) HTERT-GENE EXPRESSION regulatory gene
FR2851494B1 (fr) Perfectionnement aux fendeuses de buches
FR2885300B1 (fr) Composition topique pour la protection de l'epiderme
GB0518504D0 (en) Compositions for topical application to the body
GB0420620D0 (en) Compositions for topical application to the body
GB0320759D0 (en) Compositions for topical application to the body
GB0526264D0 (en) Improvements to the tappping of small holes
GB0411936D0 (en) 2 to 1